A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
EP072/#875 Patient-derived organoids as a preclinical platform for precision medicine in patients with cervical cancer
2022
E-Posters
unpublished
Preserved Fulltext
Conclusions This study found substantial variability in r/mCC burden at the state and MSA level. Results highlight areas in the US with disproportionately high r/mCC burden and indicate a potential gap in preventative care for women, and unmet need for education and healthcare resource allocation. Future research should evaluate associations between community-level factors and rates of r/mCC burden.
doi:10.1136/ijgc-2022-igcs.163
fatcat:bzqcluiazrg67kno7stre4wbya